Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025.
Manny brings more than 30 years of experience leading high-performing organizations and advising senior executives on large-scale corporate transformations. He currently serves as Chairman of Bain & Company, following his tenure as Worldwide Managing Partner and CEO from 2018 to 2024. In that role, he led Bain’s global strategy and operations across more than 50 offices, driving the firm’s transformation to strengthen digital capabilities, expand its focus on sustainability, and preserve its award-winning culture.
Since joining Bain in 1989, Maceda has held multiple senior leadership roles and advised CEOs across a wide range of industries on enterprise-wide initiatives spanning strategy, growth, cost management, and organizational effectiveness.
He holds a Master of Science in Management from the MIT Sloan School of Management where he serves on the advisory board, and a bachelor’s degree in chemical engineering, with High Honors, from the Illinois Institute of Technology.
“We look forward to the potential of adding Manny to our Board,” said Kevin Lobo, Chair and CEO, Stryker. “His strategic acumen, global leadership experience and track record in transformation will enhance the Board as we grow, evolve and create long-term value for shareholders.”
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.
For media inquiries:
Kim Montagnino, Vice President, Global Communications at 269-385-2600
or This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$371.86 |
| Daily Change: | -0.43 -0.12 |
| Daily Volume: | 326,575 |
| Market Cap: | US$142.210B |
October 30, 2025 October 14, 2025 September 09, 2025 July 31, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load